<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182675</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF10-00701</org_study_id>
    <nct_id>NCT01182675</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor &amp; Filgrastim</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor &amp; Filgrastim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to develop a novel approach to hematopoietic stem cell
      transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that
      eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B
      cell immune reconstitution. Rather than classic chemotherapeutic agents, the investigators
      will utilize a targeted stem cell mobilizer, plerixafor, in combination with alemtuzumab, a
      monoclonal antibody. Correlative scientific questions will include: 1) efficacy and
      characteristics of host stem cell mobilization; and 2) alemtuzumab pharmacokinetics in very
      young children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to develop an approach to hematopoietic stem cell transplantation
      for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of
      toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune
      reconstitution. SCID is a rare primary immunodeficiency disease in which there are multiple
      genotypes and phenotypes, and depending on various factors including the presence of B cell
      and NK cells, and the presence of maternal cells in the patient's circulation, there are
      numerous ways to approach a transplant. The major issues that must be addressed in any
      approach to transplantation for SCID are graft rejection and T and B cell immune
      reconstitution. Depending on the specific SCID diagnosis, the phenotype, and the presence of
      maternal engraftment at diagnosis, we will evaluate two transplant approaches that will
      attempt to optimize the engraftment of donor HSC and the likelihood of T and B cell
      reconstitution while eliminating the use of toxic chemotherapy conditioning.

        1. Primary Objective: To determine if the administration of plerixafor &amp; filgrastim (G-CSF)
           prior to stem cell infusion results in increased donor stem cell occupancy of available
           bone marrow niches and B-cell engraftment in patients with SCID.

        2. Secondary Objectives:

      i. To determine if NK cell depletion with Alemtuzumab will overcome NK-mediated graft
      resistance in haplocompatible transplants for NK+ SCID.

      ii. To determine the optimal dosing of Alemtuzumab in very young children. iii. To determine
      the immunophenotypic characteristics of CD34+ cells mobilized and engrafted in patients
      receiving plerixafor &amp; filgrastim prior to HCT.

      iv. To determine the thymic output, as measured by T-cell receptor excision circles, in
      patients receiving haplocompatible transplants &amp; boosts.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient evidence of efficacy
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment of Donor B-cells in Blood by STR Testing</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of participants in whom donor B cells were detected in the patient's blood after HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute GVHD</measure>
    <time_frame>100 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Become Independent From Regular IVIG Infusion</measure>
    <time_frame>2 Years</time_frame>
    <description>Based on B-cell function assays from the patient's blood, we will be able to determine if patients are able to successfully discontinue IVIG infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Engraftment of Donor Stem Cells in Bone Marrow by STR Testing</measure>
    <time_frame>1 Year</time_frame>
    <description>We will measure whether we are able to detect donor stem cells in the patient's bone marrow after HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Engraftment of Donor T-cells in Blood by STR Testing</measure>
    <time_frame>1 Year</time_frame>
    <description>We will measure whether we are able to detect donor T-cells in the patient's blood after HSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>T-cell Graft Permissive SCID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SCID with:
i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-cell Graft Resistant SCID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant Conditioning with Mobilization Only</intervention_name>
    <description>Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant</description>
    <arm_group_label>T-cell Graft Permissive SCID</arm_group_label>
    <other_name>Conditioning with Filgrastim and Plerixafor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant Conditioning with Mobilization and Alemtuzumab</intervention_name>
    <description>Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant</description>
    <arm_group_label>T-cell Graft Resistant SCID</arm_group_label>
    <other_name>Conditioning with Filgrastim, Plerixafor, and Alemtuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with classic SCID phenotype (&lt;400 CD3/ul or maternally engrafted and &lt;10% of
             normal PHA lymphoproliferative response). Genotypic identification is preferable, but
             not required.

          -  Patients must have an acceptable stem cell donor (HLA matched relative, 9 or 10/10
             HLA-matched unrelated, or haplocompatible relative).

        Exclusion Criteria:

          -  Patients with &quot;leaky&quot; SCID syndromes, Omenn's Syndrome, reticular dysgenesis, ADA
             deficiency

          -  Lansky score &lt;60%

          -  Patient with expected survival &lt;4 weeks (including disseminated CMV infection
             involving lungs and/or CNS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher C Dvorak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dvorak CC, Hung GY, Horn B, Dunn E, Oon CY, Cowan MJ. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2008 Oct;14(10):1125-1133. doi: 10.1016/j.bbmt.2008.07.008.</citation>
    <PMID>18804042</PMID>
  </reference>
  <reference>
    <citation>Dvorak CC, Cowan MJ. Radiosensitive severe combined immunodeficiency disease. Immunol Allergy Clin North Am. 2010 Feb;30(1):125-42. doi: 10.1016/j.iac.2009.10.004.</citation>
    <PMID>20113890</PMID>
  </reference>
  <reference>
    <citation>Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant. 2008 Jan;41(2):119-26. Epub 2007 Oct 29. Review.</citation>
    <PMID>17968328</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <results_first_submitted>October 28, 2014</results_first_submitted>
  <results_first_submitted_qc>November 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2014</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Christopher Dvorak</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>SCID</keyword>
  <keyword>Transplant</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Plerixafor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T-cell Graft Permissive SCID</title>
          <description>Patients with SCID with:
i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor
Transplant Conditioning with Mobilization Only: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant</description>
        </group>
        <group group_id="P2">
          <title>T-cell Graft Resistant SCID</title>
          <description>Patients with SCID with NK+ phenotype with HLA-mismatched donor
Transplant Conditioning with Mobilization and Alemtuzumab: Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-cell Graft Permissive SCID</title>
          <description>Patients with SCID with:
i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor
Transplant Conditioning with Mobilization Only: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant</description>
        </group>
        <group group_id="B2">
          <title>T-cell Graft Resistant SCID</title>
          <description>Patients with SCID with NK+ phenotype with HLA-mismatched donor
Transplant Conditioning with Mobilization and Alemtuzumab: Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Engraftment of Donor B-cells in Blood by STR Testing</title>
        <description>Number of participants in whom donor B cells were detected in the patient's blood after HSCT.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-cell Graft Permissive SCID</title>
            <description>Patients with SCID with:
i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor
Transplant Conditioning with Mobilization Only: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant</description>
          </group>
          <group group_id="O2">
            <title>T-cell Graft Resistant SCID</title>
            <description>Patients with SCID with NK+ phenotype with HLA-mismatched donor
Transplant Conditioning with Mobilization and Alemtuzumab: Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment of Donor B-cells in Blood by STR Testing</title>
          <description>Number of participants in whom donor B cells were detected in the patient's blood after HSCT.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute GVHD</title>
        <time_frame>100 Days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <time_frame>2 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Become Independent From Regular IVIG Infusion</title>
        <description>Based on B-cell function assays from the patient's blood, we will be able to determine if patients are able to successfully discontinue IVIG infusions.</description>
        <time_frame>2 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Engraftment of Donor Stem Cells in Bone Marrow by STR Testing</title>
        <description>We will measure whether we are able to detect donor stem cells in the patient's bone marrow after HSCT.</description>
        <time_frame>1 Year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Engraftment of Donor T-cells in Blood by STR Testing</title>
        <description>We will measure whether we are able to detect donor T-cells in the patient's blood after HSCT.</description>
        <time_frame>1 Year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T-cell Graft Permissive SCID</title>
          <description>Patients with SCID with:
i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor
Transplant Conditioning with Mobilization Only: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant</description>
        </group>
        <group group_id="E2">
          <title>T-cell Graft Resistant SCID</title>
          <description>Patients with SCID with NK+ phenotype with HLA-mismatched donor
Transplant Conditioning with Mobilization and Alemtuzumab: Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher C. Dvorak, MD</name_or_title>
      <organization>UCSF</organization>
      <phone>415-476-2188</phone>
      <email>dvorakc@peds.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

